These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
256 related items for PubMed ID: 18722651
1. No effect of statins on biochemical outcomes after radiotherapy for localized prostate cancer. Soto DE, Daignault S, Sandler HM, Ray ME. Urology; 2009 Jan; 73(1):158-62. PubMed ID: 18722651 [Abstract] [Full Text] [Related]
2. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era. Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D. Int J Radiat Oncol Biol Phys; 2005 Nov 01; 63(3):795-9. PubMed ID: 15925452 [Abstract] [Full Text] [Related]
10. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features. Vargas C, Martínez A, Galalae R, Demanes J, Harsolia A, Schour L, Nuernberg N, Gonzalez J. Prostate Cancer Prostatic Dis; 2006 Nov 01; 9(3):245-53. PubMed ID: 16786040 [Abstract] [Full Text] [Related]
11. Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality. Zelefsky MJ, Shi W, Yamada Y, Kollmeier MA, Cox B, Park J, Seshan VE. Int J Radiat Oncol Biol Phys; 2009 Dec 01; 75(5):1350-6. PubMed ID: 19515504 [Abstract] [Full Text] [Related]
16. Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy. Kollmeier MA, Katz MS, Mak K, Yamada Y, Feder DJ, Zhang Z, Jia X, Shi W, Zelefsky MJ. Int J Radiat Oncol Biol Phys; 2011 Mar 01; 79(3):713-8. PubMed ID: 20452139 [Abstract] [Full Text] [Related]
17. Pretreatment nomogram predicting ten-year biochemical outcome of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer. Zelefsky MJ, Kattan MW, Fearn P, Fearon BL, Stasi JP, Shippy AM, Scardino PT. Urology; 2007 Aug 01; 70(2):283-7. PubMed ID: 17826490 [Abstract] [Full Text] [Related]
19. External beam radiotherapy for clinically localized hormone-refractory prostate cancer: clinical significance of Nadir prostate-specific antigen value within 12 months. Ogawa K, Nakamura K, Sasaki T, Onishi H, Koizumi M, Shioyama Y, Araya M, Mukumoto N, Mitsumori M, Teshima T, Japanese Patterns of Care Study Working Subgroup of Prostate Cancer. Int J Radiat Oncol Biol Phys; 2009 Jul 01; 74(3):759-65. PubMed ID: 19327908 [Abstract] [Full Text] [Related]
20. Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer. Crook J, Ludgate C, Malone S, Perry G, Eapen L, Bowen J, Robertson S, Lockwood G. Int J Radiat Oncol Biol Phys; 2009 Feb 01; 73(2):327-33. PubMed ID: 18707821 [Abstract] [Full Text] [Related] Page: [Next] [New Search]